CombiGene delays the publication of its annual report for 2019
CombiGene AB (publ) has resolved to delay the publication of its annual report for 2019. Publication is moved from 26 May 2020 to 8 June 2020. The company’s annual general meeting will take place on 29 June 2020. Notice to attend the annual general meeting will be published later in a separate press release.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.